What I am getting at is that many theraputics in development seem to work on the idea that restoring the structure to the brain also restores its function. So amyloid beta, tau, alpha synuclein and other misfolded proteins have to be removed from around the cells in the brain for a significant theraputic benfit.
The failure in other trials is speculated that one needs to remove most of the misfolded proteins to a level prior to pathology not just Amyloid beta.
Aside from that another problem is the loss of neurons in the substantia nigra that produce dopamine in parkinsons and I'm sure other diseases also feature loss of neurons in other places. This can only be restored with future stem cell therapies.
This is why I have a few reservations about the metals hypothesis.
PBT Price at posting:
71.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)